The Patent Finder
NP

Neurobo Pharmaceuticals, Inc.

First filing 2011
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Gemphire Therapeutics Inc. (to 2020)

Nine patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2032
Next term end
7
Patent families

When these terms end

Each bar runs from grant to computed term end. 2014 to 2040.
US 8,846,761 Method for Treating Pancreatitis Feb 20, 2032
US 10,709,678 Methods of Reducing Risk of Cardiovascular Disease Jan 4, 2033
US 10,227,285 Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers Nov 16, 2035
US 10,864,238 Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders Dec 3, 2035
US 10,946,053 Composition Containing Mixed Extract of Mulberry and Poria Cocos Bark for Preventing, Improving or Treating Neurodegenerative Disorders Dec 3, 2035
US 10,588,927 Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel Jan 3, 2036
US 10,449,154 Treatment of NASH with Gemcabene Nov 7, 2036
US 9,849,104 Treatment of NASH with Gemcabene Nov 7, 2036
US 12,503,422 Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor Oct 30, 2040
201920242029203420392040
1 pending application: term is not computable until grant.Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Treatment of NASH with Gemcabene US 9,849,104
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2036.
Ends Nov 2036 · Medium confidence
Also notable
Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel US 10,588,927
Granted 2020. Computed term ends 2036.
Ends Jan 2036 · High confidence
Also notable
Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers US 10,227,285
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Ends Nov 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 22, 2027
    The maintenance fee for Treatment of NASH with Gemcabene (US 10,449,154) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel (US 10,588,927) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,846,761Method for Treating Pancreatitis
In force
 · High confidence
In forceHigh confidence
US 10,709,678Methods of Reducing Risk of Cardiovascular Disease
In force
 · High confidence
In forceHigh confidence
US 10,227,285Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers
In force
 · High confidence
In forceHigh confidence
US 10,864,238Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders
In force
 · High confidence
In forceHigh confidence
US 10,946,053Composition Containing Mixed Extract of Mulberry and Poria Cocos Bark for Preventing, Improving or Treating Neurodegenerative Disorders
In force
 · High confidence
In forceHigh confidence
US 10,588,927Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel
In force
 · High confidence
In forceHigh confidence
US 9,849,104Treatment of NASH with Gemcabene
In force
 · Medium confidence
In forceMedium confidence
US 10,449,154Treatment of NASH with Gemcabene
In force
 · Medium confidence
In forceMedium confidence
US 12,503,422Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 1 patent ended · 1 application pending · 11 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited